This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Optimized triagonists normalized body weight in DIO mice and enhanced energy expenditure more than GLP-1R mono-agonists.
Why it matters
This research highlights a promising approach to obesity treatment by targeting multiple hormonal pathways. Understanding how these peptides work could lead to more effective therapies for weight management.
How the study worked
The study involved designing unimolecular peptide triagonists and testing their effects on weight, food intake, glucose control, and energy expenditure in diet-induced obese (DIO) mice.
What this study cannot tell us
The study is based on preclinical models, so results may not directly translate to humans.
Read the original research
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
Molecular metabolism, 63, 101533
Citation
Knerr, Patrick J; Mowery, Stephanie A; Douros, Jonathan D; Premdjee, Bhavesh; Hjøllund, Karina Rahr; He, Yantao; Kruse Hansen, Ann Maria; Olsen, Anette K; Perez-Tilve, Diego; DiMarchi, Richard D; Finan, Brian. (2022). Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.. Molecular metabolism, 63, 101533. https://doi.org/10.1016/j.molmet.2022.101533